Samsara BioCapital
Latest statistics and disclosures from Samsara BioCapital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CRGX, MLYS, SRRK, NGNE, ALMS, and represent 54.85% of Samsara BioCapital's stock portfolio.
- Added to shares of these 4 stocks: ALMS (+$35M), Artiva Biotherapeutics, JSPR, Bicara Therapeutics.
- Started 3 new stock positions in ALMS, Bicara Therapeutics, Artiva Biotherapeutics.
- Reduced shares in these 7 stocks: ACLX (-$8.4M), VRNA, ELYM, IGMS, JANX, DAWN, CTNM.
- Sold out of its position in IGMS.
- Samsara BioCapital was a net buyer of stock by $23M.
- Samsara BioCapital has $520M in assets under management (AUM), dropping by 8.89%.
- Central Index Key (CIK): 0001744967
Tip: Access up to 7 years of quarterly data
Positions held by Samsara BioCapital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Samsara BioCapital
Samsara BioCapital holds 42 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cargo Therapeutics (CRGX) | 15.7 | $82M | 4.4M | 18.45 |
|
|
| Mineralys Therapeutics (MLYS) | 11.8 | $62M | 5.1M | 12.11 |
|
|
| Scholar Rock Hldg Corp (SRRK) | 10.5 | $54M | 6.8M | 8.01 |
|
|
| Neurogene (NGNE) | 10.2 | $53M | 1.3M | 41.96 |
|
|
| Alumis Common Stock (ALMS) | 6.7 | $35M | NEW | 3.3M | 10.68 |
|
| Arcellx Common Stock (ACLX) | 5.7 | $30M | -22% | 354k | 83.51 |
|
| Lenz Therapeutics (LENZ) | 5.5 | $29M | 1.2M | 23.74 |
|
|
| Nkarta (NKTX) | 3.3 | $17M | 3.8M | 4.52 |
|
|
| Eliem Therapeutics (ELYM) | 2.6 | $13M | -20% | 2.6M | 5.09 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 2.4 | $13M | 968k | 13.12 |
|
|
| Zymeworks Del (ZYME) | 2.4 | $13M | 1.0M | 12.55 |
|
|
| Acelyrin (SLRN) | 2.4 | $12M | 2.5M | 4.93 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 2.2 | $11M | 589k | 19.14 |
|
|
| Jasper Therapeutics Com New (JSPR) | 2.1 | $11M | +11% | 585k | 18.81 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.9 | $9.8M | 850k | 11.52 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 1.7 | $9.0M | 173k | 52.39 |
|
|
| Inozyme Pharma (INZY) | 1.6 | $8.2M | 1.6M | 5.23 |
|
|
| Sutro Biopharma (STRO) | 1.5 | $7.6M | 2.2M | 3.46 |
|
|
| Leap Therapeutics Com New (LPTX) | 1.2 | $6.3M | 2.4M | 2.57 |
|
|
| Gossamer Bio (GOSS) | 1.2 | $6.0M | 6.1M | 0.99 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 1.1 | $5.6M | -43% | 195k | 28.77 |
|
| Tango Therapeutics (TNGX) | 0.9 | $4.9M | 630k | 7.70 |
|
|
| Artiva Biotherapeutics Common Stock | 0.9 | $4.5M | NEW | 292k | 15.45 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.7 | $3.8M | 1.8M | 2.15 |
|
|
| Io Biotech (IOBT) | 0.7 | $3.8M | 3.6M | 1.05 |
|
|
| Vtv Therapeutics Cl A New (VTVT) | 0.5 | $2.8M | 207k | 13.56 |
|
|
| Immatics SHS (IMTX) | 0.4 | $2.3M | 198k | 11.41 |
|
|
| Prime Medicine (PRME) | 0.4 | $2.1M | 540k | 3.87 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 0.4 | $2.1M | -24% | 147k | 13.93 |
|
| Terns Pharmaceuticals (TERN) | 0.3 | $1.7M | 202k | 8.34 |
|
|
| Hillevax (HLVX) | 0.3 | $1.4M | 799k | 1.76 |
|
|
| Janux Therapeutics (JANX) | 0.2 | $1.0M | -50% | 23k | 45.43 |
|
| Bicara Therapeutics Common Stock | 0.2 | $892k | NEW | 35k | 25.47 |
|
| Aclaris Therapeutics (ACRS) | 0.2 | $801k | 696k | 1.15 |
|
|
| Lyra Therapeutics (LYRA) | 0.1 | $715k | 2.8M | 0.26 |
|
|
| Bolt Biotherapeutics (BOLT) | 0.1 | $680k | 1.0M | 0.65 |
|
|
| Viracta Therapeutics (VIRX) | 0.0 | $160k | 690k | 0.23 |
|
|
| Allakos (ALLK) | 0.0 | $112k | 172k | 0.65 |
|
|
| Kronos Bio (KRON) | 0.0 | $78k | 78k | 1.00 |
|
|
| Allovir (ALVR) | 0.0 | $67k | 82k | 0.81 |
|
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $13k | 133k | 0.10 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.0k | 100k | 0.01 |
|
Past Filings by Samsara BioCapital
SEC 13F filings are viewable for Samsara BioCapital going back to 2018
- Samsara BioCapital 2024 Q3 filed Nov. 14, 2024
- Samsara BioCapital 2024 Q2 filed Aug. 14, 2024
- Samsara BioCapital 2024 Q1 filed May 15, 2024
- Samsara BioCapital 2023 Q4 filed Feb. 14, 2024
- Samsara BioCapital 2023 Q3 filed Nov. 14, 2023
- Samsara BioCapital 2023 Q1 restated filed Aug. 14, 2023
- Samsara BioCapital 2023 Q2 filed Aug. 14, 2023
- Samsara BioCapital 2023 Q1 filed May 15, 2023
- Samsara BioCapital 2022 Q4 amended filed Feb. 15, 2023
- Samsara BioCapital 2022 Q4 filed Feb. 14, 2023
- Samsara BioCapital 2022 Q3 filed Nov. 14, 2022
- Samsara BioCapital 2022 Q2 filed Aug. 15, 2022
- Samsara BioCapital 2022 Q1 filed May 16, 2022
- Samsara BioCapital 2021 Q4 filed Feb. 14, 2022
- Samsara BioCapital 2021 Q3 filed Nov. 15, 2021
- Samsara BioCapital 2021 Q2 filed Aug. 17, 2021